Jilin Aodong Pharmaceutical Group Co., Ltd.
000623
Rang in Aktien
#4851
Jilin Aodong Pharmaceutical Group Co., Ltd. operates in China, principally... Jilin Aodong Pharmaceutical Group Co., Ltd. operates in China, principally focusing on the production and distribution of a broad spectrum of pharmaceutical goods. Its product line encompasses various drug forms like oral liquids, injections, capsules, granules, pills, and tablets, as well as traditional Chinese herbal medicines, powders, syrups, and spirits. The company also produces specialized medicinal products, including enzymes, biochemical drugs, and plant-based chemical medicines. In addition to its core pharmaceutical activities, Jilin Aodong diversifies its operations across several other sectors. These include highway construction and toll management, animal husbandry, the creation of specialty chemicals, and the provision of heat and water. The company further engages in the wholesale, retail, and distribution of medicines, packaging design and printing, the manufacturing of medicinal packaging materials, and delivers information consulting and advertising design solutions. Founded in 1957, its corporate headquarters are situated in Dunhua, China.
Aktienkurs
$2.55
Marktkapitalisierung
$3.05B
Veränderung (1 Tag)
3.33%
Veränderung (1 Jahr)
-11.84%
Land
CN
Handel Jilin Aodong Pharmaceutical Group Co., Ltd. (000623)
Kategorie
Healthcare
Umsatz von Jilin Aodong Pharmaceutical Group Co., Ltd. (000623)
Umsatz im Jun 2026 TTM: $324.58M
Laut den aktuellen Finanzberichten von Jilin Aodong Pharmaceutical Group Co., Ltd. beträgt der derzeitige Umsatz des Unternehmens (TTM) $324.58M. Im Jahr 2023 erzielte das Unternehmen einen Umsatz von $487.26M eine Steigerung gegenüber dem Umsatz im Jahr 2022, der $415.81M betrug. Der Umsatz ist der Gesamtbetrag, den ein Unternehmen durch den Verkauf von Waren oder Dienstleistungen erzielt. Im Gegensatz zum Gewinn werden keine Ausgaben abgezogen.
Umsatzverlauf für Jilin Aodong Pharmaceutical Group Co., Ltd. von 2000 bis 2026
Umsatz am Ende jedes Jahres
| Jahr | Umsatz | ändert |
|---|---|---|
| 2026 (TTM) | $324.58M | -9.25% |
| 2024 | $357.66M | -26.60% |
| 2023 | $487.26M | 17.18% |
| 2022 | $415.81M | 14.72% |
| 2021 | $362.46M | 5.16% |
| 2020 | $344.67M | -22.29% |
| 2019 | $443.52M | -8.22% |
| 2018 | $483.25M | 5.62% |
| 2017 | $457.53M | 16.07% |
| 2016 | $394.17M | 9.63% |
| 2015 | $359.54M | -0.59% |
| 2014 | $361.66M | 12.10% |
| 2013 | $322.61M | 39.17% |
| 2012 | $231.80M | 27.60% |
| 2011 | $181.66M | 7.70% |
| 2010 | $168.67M | 12.29% |
| 2009 | $150.21M | 10.47% |
| 2008 | $135.97M | 17.47% |
| 2007 | $115.75M | 17.31% |
| 2006 | $98.67M | 3.79% |
| 2005 | $95.06M | -4.15% |
| 2004 | $99.18M | 21.83% |
| 2003 | $81.41M | 17.43% |
| 2002 | $69.33M | 28.70% |
| 2001 | $53.87M | 41.79% |
| 2000 | $37.99M | 0.00% |
Umsatz vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Umsatz | Umsatzunterschied | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 1,936.98% |
IN
|
